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Abstract
Recent studies have evaluated proper
acquisition and storage procedures for the use
of serum or plasma for mass spectrometry
(MS)-based proteomics. The present study
examines the proteome stability of human cere-
brospinal fluid (CSF) over time at 23°C (room
temperature) and 4°C using surface-enhanced
laser desorption/ionization time-of-flight MS.
Data analysis revealed that statistically signifi-
cant differences in protein profiles are apparent
within 4 h at 23°C and between 6 and 8 h at
4°C. Inclusion of protease and phosphatase
inhibitor cocktails into the CSF samples failed
to significantly reduce proteome alterations
over time. We conclude that MS-based pro-
teomic analysis of CSF requires careful assess-
ment of sample collection procedures for rapid
and optimal sample acquisition and storage.
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Introduction
Biomarker discovery is at the forefront of
biomedical research, and mass spectrometry
(MS)-based clinical proteomics has become a
popular method to both streamline drug 
discovery and provide specific diagnostic
biomarkers and surrogate end points for a
number of human diseases (1–7). However,
the ability of MS (or other proteomic tech-
niques) to accurately characterize the pro-
teome is dependent on the extent to which the
clinical samples were appropriately handled
and stored to preserve protein and peptide
integrity. Clinical samples are often initially
stored either at room temperature or on ice
for various lengths of time before being
received by a research laboratory for final
sample preparation and long-term storage.
Prior studies have shown that sample han-
dling and storage conditions are critical vari-
ables in protein analysis of blood serum,
urine, and tissue samples (8–12). Another
study demonstrated that reproducible and
reliable measurements of apolipoprotein E
within the cerebrospinal fluid (CSF) were
dependent on consistent sample handling and
storage conditions (13). 
Many ongoing proteomic biomarker dis-
covery and validation studies are collaborative
multicenter projects, which can confound
efforts to apply consistent sample acquisition
and storage conditions, especially if samples
are obtained through surgical procedures. Any
preanalytical errors or procedural differences
between the various participant sites, or even
the adoption of uniform but suboptimal,
untested platform standardization strategies,
will ultimately affect the final data analysis
and potentially lead to erroneous identifica-
tion of “artifact” biomarkers (14,15). It is,
therefore, crucial to characterize the impact of
sample collection, handling, and storage proce-
dure and identify best laboratory practices to
reduce experimental variation and enhance
quality control, even at the biomarker discovery
stage.
Despite many clinical proteomic studies
using CSF (4,16–18), there are no reports on
the stability of the CSF proteome over time
when incubated at various temperatures. A
prior study identified instabilities of CSF
metabolites by proton nuclear magnetic res-
onance after 72-h exposure to room tempera-
ture (19). A number of age-related changes 
in the CSF proteome have been recently
reported; an important consideration for 
age-dependent disease processes, such as
neurodegenerative disorders (20). Tempera-
ture storage-related artifacts have also been
reported for the cystatin C protein within
human CSF (15). Prefractionation of CSF via
chromatography or gel electrophoresis has
also been used to analyze its proteomic con-
tent (21). Recent investigations have also
examined proper collection and storage pro-
cedures for plasma proteomics using two-
dimensional (2D) gels or matrix-assisted
laser desorption/ionization time-of-flight
(MALDI-TOF)-MS (22,23), or highlighted fac-
tors affecting the reproducibility of protein
profiling in urine many months after initial
examination (3). In addition, a recent study
evaluated the presence of blood protein con-
taminants in the CSF using 2D gels and
determined that CSF proteins of blood con-
taminated samples were less stable than CSF
proteins with no blood contamination (24). A
current report has demonstrated the repro-
ducibility of the surface-enhanced laser des-
orption/ionization  (SELDI)-TOF-MS protein
profiling system across multiple laboratories
using human serum (14). The aim of the cur-
rent study was to evaluate the stability of the
CSF proteome to variations of temperature
and time, as determined by SELDI-TOF-MS
protein profiling. 
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Methods
Samples
CSF was obtained by lumbar puncture from
four healthy adults (three female, one male,
age range from 17 to 65 yr) on University of
Pittsburgh approved institutional review board
consent. Subject 1 is a 17-yr-old female, subject
2 is a 56-yr-old female, subject 3 is a 65-yr-old
female, and subject 4 is a 32-yr-old male.
Immediately after lumbar puncture, the CSF
was centrifuged at 800g for 5 min at 4°C to
remove any cellular debris, and either directly
used for analysis or stored frozen in small vol-
umes at –80°C. As a measure for blood con-
tamination, we examined the presence of
hemoglobin protein peaks by MS. CSF samples
used in this study lacked evidence of blood
contamination. Aliquots of frozen CSF were
thawed on ice immediately prior to use. For
the current study, one experimental group
used CSF immediately after lumbar puncture
and the second experimental group used CSF
that had been exposed to one freeze/thaw
cycle. A third experimental group contained
Protease Inhibitor Cocktail (Sigma) and phos-
phatase inhibitor cocktails (Calbiochem Phos-
phatase inhibitor Set II) added directly to the
sample after thawing the sample on ice to
evaluate proteome instability caused by pro-
teolysis or dephosphorylation.
Study Design
Within each experimental group, two
sample sets were prepared for analysis. Each
sample set contained seven replicate tubes
containing 20 µL of CSF for each of eight time
points: 0, 2, 4, 6, 8, 12, 16, and 24 h. One
sample set was incubated at 23°C for the des-
ignated time points. The second sample set
was incubated at 4°C for the appropriate time
points. The third experimental group contain-
ing protease and phosphatase inhibitors was
incubated at 23°C. At each time point, all sam-
ples were prepared immediately for protein
profiling on the strong anion exchange (Q10)
ProteinChips (Ciphergen Biosystems, Inc.,
Palo Alto, CA) as follows. Ten microliters of
urea buffer (9 M urea/2.5% CHAPS) were
added to each sample, vortexed, and 170 µL
of HEPES, pH 7.3 were added. The samples
were then placed on a micromix shaker for 
10 min. The Q10 ProteinChips were placed in
a bioprocessor (Ciphergen Biosystems, Inc.)
and first equilibrated with 100 mM HEPES pH
7.3 for 10 min and excess buffer removed from
the spots. One hundred microliters of sample
were then applied to each well and incubated
for 30 min. Replicate samples were applied
in random order to the chip arrays. The Pro-
teinChips were washed five times in high-
performance liquid chromatography-grade
water. Excess water was removed and two
applications of 1.5 µL of sinapinic acid in
50% acetonitrile/0.3% v/v trifluoroacetic
acid was added to each spot and the arrays
were air dried. 
Mass Spectrometry
The Q10 arrays were then read in a Cipher-
gen PBS IIC Chip reader system containing an
autoloader (Ciphergen Biosystems). Spectra
were generated using a laser intensity range
of 190 and a detector sensitivity range of 8 to 9
with a mass deflector setting of 1000 Da for
the low-mass range (1–20 kDa). These settings
were kept constant for all chips analyzed in an
experiment. Two mass spectra were obtained
for each sample: one for the mass range from
1 to 20 kDa, and a second for the mass range
from 20 to 160 kDa. For each Q10 ProteinChip
array, a standard CSF sample was loaded onto
one spot to measure chip-to-chip variability.
The coefficient of variance (COV) for four
selected m/z signals was less than 30% across
all chip arrays. External calibration of the spec-
trometer was performed using the “7-in-1”
peptide mix from Ciphergen Biosystems (vaso-
pressin [1084.247 Da], somatostatin [1637.903
Da], porcine dynorphin A [2147.5 Da], human
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ACTH [2933.5 Da], bovine insulin B chain
[3495.941 Da], human recombinant insulin
[5807.633 Da], and hirudin [7033.614 Da]).
Human SOD1 (15591.4 Da) was also added to
this mix. 
Data Analysis
Protein profile comparisons were made
after normalization of each spectrogram to
total ion current, and raw spectral data con-
sisted of 18,400 mass peak values for each
individual sample. All samples within each
sample set were prepared and analyzed at the
same time within the same experiment. Spec-
tra were analyzed using Ciphergen Pro-
teinChip software (v3.2.1). Statistical analysis
of all mass peaks was performed using the
nonparametric Mann-Whitney test on the
maximal intensity of each peak. Peak labeling
was performed using second-pass peak selec-
tion with a signal-to-noise ratio of 1.5. Signifi-
cance threshold was set of p < 0.05. 
Results
We first analyzed the SELDI-TOF-MS spec-
tra of human CSF incubated at 23°C between 0
and 24 h. Figure 1 represents typical spectra
between 2.5 and 20 kDa. Low-molecular mass
m/z peaks between 3 and 8 kDa exhibit alter-
ations that are evident at early time points and
are most prominent by 24 h (Fig. 1). Spectral
peaks near 14 kDa also exhibit significant peak
intensity value alterations by 4 h at 23°C. We
next examined and compared the spectral pat-
tern of an identical CSF sample incubated at
either 23 or 4°C.
Figure 2 depicts typical SELDI-TOF-MS
spectra of human CSF for each time point at
both 23°C (left panels) and 4°C (right panels).
For display purposes, we have magnified the
spectral region between 11 and 15 kDa for rep-
resentative spectra at each time point and tem-
perature. As noted in the Methods section, we
analyzed seven replicate samples for each time
point and Fig. 2 displays the representative
spectra. Although small differences in average
peak intensity levels are apparent for specific
m/z peaks at various time points, we have
highlighted one region of m/z peaks that
exhibit significant variation over time at each
temperature. The peaks between 13.7 and 14.1
kDa highlighted by “a” at 0 h resolve to a
doublet (*) by 6  at 23°C. 
At 4°C, the peaks between 13.7 and 14.1
kDa highlighted by “a” at 0 h resolve to a pro-
tein doublet (*) by 8–12 h at 4°C (Fig. 2, left
panels). Finally, the spectrum observed after 
6 h at 23°C is almost identical to the spectrum
obtained after 16–24 h at 4°C (Fig. 2). Similar
results were obtained for CSF samples that
were exposed to one freeze/thaw cycle prior
to analysis (data not shown). These data indi-
cate that specific m/z peaks exhibit alterations
over time regardless of the temperature but
the stability of the CSF proteome is enhanced
by maintaining samples at 4°C. The integrity
of the mass spectral pattern may be main-
tained an additional 4–6 h by storing CSF
samples at 4°C as opposed to 23°C. 
We next determined if the addition of pro-
tease inhibitor and phosphatase inhibitor cock-
tails to the CSF would impede protein profile
changes that occur over time. Spectra between
4 and 17 kDa for CSF incubated at 23°C
between 0 and 8 h in the presence or absence of
protease and phosphatase inhibitors are shown
in Fig. 3. In the absence of any inhibitors, alter-
ations in protein relative peak intensity values
are evident within 2 h (Fig. 3A), similar to those
described in Figs. 1 and 2. Immediately after
addition of the cocktail inhibitors, many m/z
peak intensity values exhibit decreased relative
peak intensity, possibly as a result of the sup-
pression of protein ionization from the protein
chip surface (Fig. 3B). Other protein/peptide
peaks near 7 kDa exhibit a transient increased
relative peak intensity value. However, pro-
tein peak alterations are evident by 2 h even
in the presence of protease and phosphatase
inhibitors for peaks near 14 kDa, and the
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spectral pattern for lower-molecular mass
peaks is similar to that observed without pro-
tease and phosphatase inhibitors (Fig. 3). The
overall consistency of the spectral peak pattern
between 0 and 8 h was higher for CSF lacking
protease or phosphatase inhibitors. Similar
results were observed using two different con-
centrations of inhibitors within the experiment.
Therefore specific m/z peak changes that occur
in CSF over time as detected by SELDI-TOF-
MS are unlikely to be induced by protease or
phosphatase activities.
To quantify proteomic changes over time,
we first determined the average m/z peak
intensity value and standard deviation using
the seven replicate samples at each time point
for the 23 and 4°C CSF samples. To character-
ize the trend in among-sample variability
within each time point, we determined the
variance (VAR) and the COV of each m/z
position among profiles at each time point
within each temperature data set. VAR is a mea-
surement of the overall variation of the peak
intensity values for a given m/z, and is com-
puted as the average squared deviation for each
m/z peak intensity value from the mean peak
intensity value. VAR at 4°C increases slowly for
the first 8 h, then plateaus and finally peaks 
Fig. 1. SELDI-TOF-MS spectra of human CSF (subject 3, see Methods) incubated for various times at 23°C.The
representative m/z profiles between 2.5 and 20.0 kDa are shown for 0, 2, 4, 6, 8, 12, 16, and 24 h.
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at 24 h (Fig. 4A). This data suggest a high
degree of reproducibility within spectra for
individual samples at each time point. Even at
23°C, the variance at different time points
remains low, again suggesting that any
changes occurring within the proteome occur
at a consistent rate within the replicate sam-
ples at each time point. COV at each m/z
position was calculated as the standard devia-
tion over the mean of each variance. Again,
the COV measure exhibits no particular trend
at either temperature, suggesting that repro-
ducibility within each time point is quite good
(Fig. 4B). The observed small changes may
reflect variation in baseline within the time
points. 
The COV for each time point were then
used to calculate a whole-profile grand mean
sum of mean deviation (GMSD) from the 0-h
time point of each temperature. The GMSD
was calculated as the sum of all mean of
squared differences between each position in
Fig. 2. SELDI-TOF-MS spectra from Q10 chips of human CSF (subject 4, see Methods) incubated for various
times at either 4°C (left panels) or 23°C (right panels).The m/z profiles between 11.0 and 17.0 kDa are
shown for 0, 2, 4, 6, 8, 12, 16, and 24 h.The arrow and region marked by “a” indicate m/z peaks exhibiting either
alteration in relative peak intensity or peak resolution over time. * marks the presence of a protein peak dou-
blet present at 6 h at 23°C that is apparent at 8–12 h at 4°C.
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the mean profile at each time point and the
mean profile at 0-h for each temperature 
(Fig. 5). GMSD from the 0-h time point
exhibits an overall increasing trend at each
temperature. For the 4°C samples, increased
variability is initially observed at 8 h, suggest-
ing proteomic alterations have occurred within
8 h at this temperature. For the 23°C samples,
there are proteome alterations within 4 h as
depicted by increased GMSD and then a large
increase in GMSD occurs between 16 and 24 h
(Fig. 5). The large increase in GMSD may
reflect additional alterations of low-molecular
mass peaks during this time period as evident
Fig. 3. Protease and phosphatase inhibitors fail to impede proteomic alterations over time at 23°C. CSF from
subject 3 was incubated at 23°C for various lengths of time in the absence (A) or presence (B) of protease
and phosphatase inhibitors.The m/z profiles between 11.0 and 15.0 kDa are shown for 0, 2, 4, and 8 h. (A)
Proteomic alterations that occur over time at 23°C are similar to that observed in Fig. 1, even though the CSF
is from a separate subject. (B) Addition of protease and phosphatase inhibitors results in immediate decreased
peak intensity values for many m/z peaks at 0 h, although similar peak alterations occur at 4 and 8 h to CSF in
the absence of inhibitors.
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in Fig. 1. These results suggest the proteome
instability is more rapid and extensive at 23°C
as compared to 4°C. 
Discussion
The goal of this study was to define proce-
dures that preserve proteomic stability of clin-
ical samples and minimize artifacts that may
arise when using MS-based proteomics to
identify CSF-based biomarkers. Our results
indicate that significant CSF proteomic alter-
ations occur within 2–4 h at 23°C and within
6–8 h at 4°C. Further protein peak alterations
were evident at later time points, most promi-
nent in low-molecular weight species between
2 and 8 kDa. The addition of protease and
Fig. 4. (A) Variance of the m/z values within all replicate samples at each time point. For each time point, the
average m/z peak intensity value and standard deviation was determined for each of the 18,400 mass peaks
within the raw spectral data for all replicate samples. The average overall variance was then determined for
each time point and represented as the percent variance with corresponding standard error of mean. (B) The
coefficient of variance for each time point was then determined as the ratio of standard deviation over its
mean for each time point. Dashed lines represent 23°C (room temperature) and solid lines 4°C samples in
each panel. RT, room temperature.
07_Bowser.qxd  11/21/06  3:19 PM  Page 98
Volume 2, 2006 ________________________________________________________________ Clinical Proteomics
Proteome Stability of CSF ____________________________________________________________________ 99
phosphatase inhibitor cocktails resulted in an
immediate suppression of many spectral
peaks, possibly because of suppression of pro-
tein ionization. Within 2 h, low-molecular
mass peaks were now evident in CSF contain-
ing the inhibitor cocktails (Fig. 3B), although
continued suppression of peak ionization was
evident in many samples (data not shown).
The presence of protease and phosphatase
inhibitors failed to impede proteomic alter-
ations significantly over time, although the
presence of specific mass ion peaks was
delayed by 2–4 h. Because the overall consis-
tency of the mass spectral data, especially at
the early time points between 0 and 8 h, was
greater in samples lacking inhibitor cocktails,
we suggest that rapid CSF recovery, prepro-
cessing, and storage at –80°C will generate
more stable mass spectral data than CSF with
added protease and phosphatase inhibitors.
However, the observed proteomic alterations
may be induced by enzymatic activities not
targeted by the inhibitor cocktails used in this
study. Future studies will purify individual
m/z peaks that change over time to determine
their protein identity and potential mecha-
nisms that induce the proteomic alterations.
These findings are also important because it
appears likely that proteomic biomarker pat-
terns associated with disease, disease progres-
sion, and therapy responses may reflect
biochemical interrelationships among peptides
or proteins, which can be expected to change
with temperature and time. 
Therefore, care should be taken to monitor
carefully the time necessary to harvest and
process CSF samples until they are preferably
snap-frozen and properly stored at –80°C. 
Although many m/z peaks were quite stable
even up to 24 h, variability within sample
preparation and handling procedures may
introduce significant protein alterations such
that final mass spectral data analysis is difficult
to properly interpret. Exposure of CSF samples
to ambient temperatures should be minimized
to maintain stability of the proteome within
individual samples. Recent evidence suggests
that ex vivo proteolytic processing of serum
proteins results in peptide patterns characteris-
tic for myocardial infarction (23). Our protocol
Fig. 5. Statistical comparison for the proteome stability at each time point to the 0-h time point. For both 23°C
(room temperature [RT], dashed line) and 4°C (solid line) samples, the difference between the mean profiles
at each time point relative to the 0-h time point mean profile was calculated as the grand mean sum devia-
tion. This value, representing the cumulative departure from initial conditions, was plotted for each of the
seven time points.At 23°C, changes in proteome stability when compared to the 0-h time point occur within
3 h and peak between 16 and 24 h. Proteome instability at 4°C is not apparent until the 8-h time point.
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for rapid processing of CSF at 4°C provides one
approach to reduce sample-to-sample proteome
variability that may well result in the identifi-
cation of “artifact” protein biomarkers. 
Conclusion
Our data highlight the importance in iden-
tifying and following appropriate and consis-
tent sample collection procedures when
preparing clinical samples for proteomic anal-
ysis. CSF sample preprocessing time should be
kept to less than 4 h and samples maintained
at 4°C prior to long-term storage at –80°C to
generate high-quality CSF samples for pro-
teomic analysis. 
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